BREAKTHROUGH STUDY REVEALS VARENICLINE AND COUNSELING EFFECTIVE FOR DUAL USERS IN SMOKING CESSATION
The study found that the antismoking medication varenicline can increase rates of smoking abstinence without causing serious adverse events.
The study found that the antismoking medication varenicline can increase rates of smoking abstinence without causing serious adverse events.
In their work “Respiratory health effects of e-cigarette substitution for tobacco cigarettes: a systematic review”, researchers analyzed 16 studies from 20 publications: most of the studies showed no difference in respiratory parameters. This indicates that electronic nicotine delivery systems substitution for smoking likely does not result in additional harm to respiratory health.
Replica researchers performed a standard toxicology battery of three assays used for product assessment and regulatory applications.
The DiaSmokeFree Working Group send a letter to the American Diabetes Association (ADA) expressing concern and seeking correction of a couple of statements in the ADA guidelines regarding the use…
Today has been released the report “Lives Saved Report - Integrating harm reduction into tobacco control”, indicating that significant lives can be saved through the widespread adoption of THR and…
Professor Li Volti talked about the Replica project results with a presentation titled "The impact of cigarette smoke and reduced risk products aerosol on endothelial function: the REPLICA project"
At 11.15 am, October 19, prof. Polosa will host remotely the panel Longer Term Outcomes of Cessation and Harm Reduction with a presentation on "Changes in Health Symptoms - Results and Analysis Methodologies".
“𝑊𝑒 𝑛𝑒𝑒𝑑 𝑡𝑜 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑒 𝑡𝑜𝑔𝑒𝑡ℎ𝑒𝑟 𝑠𝑜 𝑡ℎ𝑎𝑡 𝑒𝑣𝑒𝑟𝑦 𝑠𝑖𝑛𝑔𝑙𝑒 𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑏𝑒𝑐𝑜𝑚𝑒𝑠 𝑎𝑛 𝑒𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑡𝑜𝑜𝑙. 𝑊𝑒 𝑑𝑜𝑛'𝑡 𝑤𝑎𝑛𝑡 𝑡𝑜 𝑝𝑢𝑛𝑖𝑠ℎ 𝑎𝑢𝑡ℎ𝑜𝑟𝑠 𝑓𝑜𝑟 𝑡ℎ𝑒𝑖𝑟 𝑗𝑢𝑛𝑘 𝑝𝑎𝑝𝑒𝑟𝑠, 𝑤𝑒 𝑤𝑎𝑛𝑡 𝑡𝑜 𝑝𝑟𝑜𝑣𝑖𝑑𝑒 𝑡ℎ𝑒 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑡𝑜 𝑖𝑚𝑝𝑟𝑜𝑣𝑒”
The findings presented by CoEHAR researchers can contribute the discussions of ENDS for cessation and support harm reduction strategies in the world.
The conference will bring together leading experts in the field to discuss the latest research on dyslipidemias and their management. Topics to be covered include the latest guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), as well as innovative topics such as environmental risk factors, including smoking, and their role in the progression of atherosclerosis.